New High Volume Breath Biopsy Lab opening with Tony Blair
17 Mar 2017
We welcomed former UK prime minister Tony Blair to our headquarters in Cambridge, UK where he officially opened our new high volume clinical laboratory. The new facilities will enable high quality and high throughput Biomarker Services, for identification of novel breath biomarkers in disease diagnostics and precision medicine applications.
During the visit, Mr Blair toured our state-of-the-art facilities and learned more about the company’s Breath Biopsy® technology and its mission to save 100,000 lives and $1.5 billion in healthcare costs.
The opening of the new clinical lab increases Owlstone Medical's capacity to offer high quality and high throughput Biomarker Services to academics, clinicians, pharmaceutical companies and CROs to identify novel breath biomarkers for disease diagnostics as well as precision medicine applications including therapeutic response, patient stratification and outcome prediction.
The clinical lab also provides VOC biomarker analysis of breath samples and other biospecimens from the on-going clinical trials in Owlstone Medical’s own clinical pipeline: early detection of lung cancer (LuCID), colorectal cancer (InTERCEPT) and treatment stratification in asthma (STRATA).